BeiGene, Ltd. is a global biotechnology company founded in 2010, focused on the discovery and development of innovative oncology treatments aimed at improving accessibility and affordability for cancer patients worldwide. Based in Beijing, with a presence in the United States and beyond, BeiGene has established one of the largest oncology research teams globally, employing over 9,200 professionals. The company’s commercial portfolio includes BRUKINSA, a BTK inhibitor approved for various blood cancers, and Tislelizumab, an anti-PD-1 antibody currently under regulatory review for advanced esophageal squamous cell carcinoma. BeiGene's extensive pipeline encompasses a wide range of cancer therapies targeting multiple malignancies, including acute myeloid leukemia, multiple myeloma, and solid tumors. In addition to its therapeutic development, the company actively engages in programs that address the broader needs of oncology patients, such as mental health awareness initiatives. Through its commitment to innovation and patient care, BeiGene aims to significantly impact cancer treatment and improve outcomes for patients around the globe.
Duo Oncology is focused on developing innovative nanoparticle technology designed to effectively penetrate established tumors, particularly in challenging cases such as pancreatic and bile duct cancers. The company aims to transform treatment outcomes through a novel monotherapy that enhances patient care for those with hard-to-treat tumors and relapsed metastatic disease. By collaborating with leading university scientists and medical oncologists, Duo Oncology leverages a network of established research organizations to expedite the development of its products. The technology addresses significant needs in immunotherapy and precision medicine, ultimately striving to improve recovery times and patient outcomes.
Strand Therapeutics
Series A in 2021
Strand Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2017. The company focuses on genetically programming mRNA to develop innovative therapies that enhance patient outcomes. Utilizing its mRNA programming technology, Strand Therapeutics creates gene therapies powered by synthetic biology, which include immunotherapies designed to stimulate cells to produce cancer-targeting proteins. This approach improves the immune system's ability to combat cancer by enabling precise control over the timing, location, and intensity of therapeutic protein expression. The technology leverages cell-type specific expression and responds to specific molecular signals, allowing for tailored therapeutic interventions.
Boston Immune Technologies & Therapeutics
Series A in 2021
Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company founded in 2011 and located in Winchester, Massachusetts. The company focuses on developing immune-based therapies for cancer and chronic infectious diseases. A key aspect of its research involves targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and addressing the specific population of TNFR2 regulatory T cells present in the tumor microenvironment. Through its innovative approaches, Boston Immune Technologies aims to advance immunotherapy options for patients facing these challenging health conditions.
Singlomics
Series A in 2020
Singlomics is a biotechnology company that specializes in single-cell sequencing technology to facilitate antibody drug development aimed at treating infectious diseases and cancers. The company has made significant advancements in antibody discovery, having developed neutralizing antibodies such as DXP593 and DXP604, which offer potential solutions in the fight against COVID-19. By leveraging its innovative technology, Singlomics focuses on creating targeted therapies that address critical health challenges.
Leap Therapeutics
Post in 2020
Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of targeted and immuno-oncology therapies for cancer treatment. Founded in 2011 and previously known as HealthCare Pharmaceuticals, the company focuses on identifying and developing molecules that inhibit tumor-promoting pathways and activate the immune system against cancer cells. Its lead program, DKN-01, is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1) and is currently undergoing clinical trials for various cancers, including esophagogastric and gynecologic cancers. Additionally, Leap Therapeutics is advancing its second program, FL-301, which targets Claudin18.2-expressing cells, along with two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative treatments for cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.